Today's Research Reports on Stocks to Watch: Capricor Therapeutics and Immunocellular Therapeutics
NEW YORK, NY / ACCESSWIRE / July 19, 2017 / Capricor Therapeutics was a big winner in trading on Tuesday with shares seeing gains of over 100%. The company announced that its drug candidate for the treatment of Duchenne muscular dystrophy, CAP-1002, was granted Rare Disease Designation by the FDA. Shares of Immunocellular Therapeutics saw a big crash yesterday after announcing the pricing of a public offering.
RDI Initiates Coverage on:
Capricor Therapeutics, Inc.
https://ub.rdinvesting.com/news/?ticker=CAPR
ImmunoCellular Therapeutics, Ltd.
https://ub.rdinvesting.com/news/?ticker=IMUC
Capricor Therapeutics, Inc. was one of the biggest gainers on the NASDAQ in Tuesday trading. The stock closed up 102.99% on incredible trading volume compared to usual. Yesterday the stock saw over 32 million shares traded compared to an average of just around 110,000 shares. The big move came after the company revealed that the FDA has granted CAP-1002, its candidate for the treatment of Duchenne muscular dystrophy, Rare Disease Designation. The drug has already received Orphan Drug Designation. CEO Linda Marban, Ph.D. commented, "The Rare Pediatric Disease Designation adds to our previous Orphan Drug Designation for CAP-1002 for the treatment of Duchenne muscular dystrophy, which together underscore the urgent need for treatment options for this devastating rare disease as well as provide Capricor with certain incentives for their development. We believe CAP-1002 has the potential to provide meaningful clinical benefit to patients. We look forward to commencing our next clinical trial in DMD, for which design will be relevant to the overall registration plan for this candidate."
Access RDI's Capricor Therapeutics, Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=CAPR
ImmunoCellular Therapeutics, Ltd. was one of the biggest losers on the NYSE yesterday, with shares closing down a little over 60%. The stock even hit a new low of $0.45 during intra-day trading. Earlier in the day, the company announced in a press release the pricing of an underwritten public offering of 5,000 shares of its Series B 8% Mandatorily Convertible Preferred Stock and related warrants to purchase up to 9,000 shares of Preferred Stock. The public offering price is $1,000 per share of Preferred Stock and related Warrants, for gross proceeds of approximately $5 million, excluding the proceeds, if any, from the exercise of the Warrants. At the end of last month, the company had to suspend a phase 3 trial of ICT-107, its lead cancer vaccine, due to the fact that the company had not raised enough money to complete the study. The company had said it was not only looking for a commercial partner for the trial, but also was looking for "financing and strategic alternatives for its immuno-oncology R&D pipeline and technology platform."
Access RDI's ImmunoCellular Therapeutics, Ltd. Research Report at:
https://ub.rdinvesting.com/news/?ticker=IMUC
Our Actionable Research on Capricor Therapeutics, Inc. (NASDAQ: CAPR) and ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer or a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
